Abstract
Down's syndrome (DS), the most frequent of congenital birth defects, results from the trisomy of chromosome 21 in all cells of affected patients. This disease is characterized by developmental anomalies, mental retardation and features of rapid aging, particularly in the brain, where the occurrence of Alzheimer's disease is observed in trisomy 21 patients over the age of 35. Copper-zinc superoxide dismutase (CuZnSOD) is one of the proteins encoded by chromosome 21 (21q22.1). As a consequence of gene dosage excess, CuZnSOD activity is increased by 50% in all DS tissues. This work reports the SOD activity of a population of DS patients with complete trisomy 21, partial trisomy 21, translocations and mosaicism, in order to confirm the gene dosage effect of SOD on the clinical features of DS, and to help to establish which is the critical region of chromosome 21 in DS. CuZnSOD was measured in red blood cells using the Minami and Yoshikawa method. In the population with complete trisomy 21, SOD activity was increased by 42%; in the population with partial trisomy 21, translocations and mosaicism, SOD activity was normal. In the population diagnosed as DS, but not karyotyped, SOD activity was increased by 28%. No differences between sexes or among ages were found. We conclude that the 21q22.1 segment is not the critical region responsible for DS, as we have found normal SOD activity in patients with the clinical features of DS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Lejeune, J., Gautier M. and Turpin R. (1959) Etude des chromosomes somatiques de 9 enfants mongoliens. C. R. Acad. Sci. Paris248: 1721–1728
Hook E. B. (1981) Down's syndrome-frequency in human populations and factors pertinent to variation in rates. In: Trisomy 21 (Down's Syndrome): Research Perspectives, pp. 3–68, de la Cruz F. F. and Gerarld P. S. (eds), University Park Press, Baltimore
Epstein C. J. (1986) The Neurobiology of Down's Syndrome, Raven Press, New York
Fridovich I. (1986) Advances in enzymology and related areas of molecular biology. In Superoxide Dismutases, vol. 58, pp. 61–97, Meister A. (ed.), John Wiley & Sons Inc., New York
Francke U. (1981) Gene dosage studies in Down's syndrome: a review. In: Trisomy 21 (Down's Syndrome): Research Perspectives, pp. 237–251, de la Cruz F. F. and Gerarld P. S. (eds), University Park Press, Baltimore
Sherman L., Dafni N., Lieman-Hurwitz J. and Groner Y. (1983) Nucleotide sequence and expression of human chromosome 21-encoded superoxide dismutase mRNA. Proc. Natl Acad. Sci. USA80: 5465–5469
Badwey J. A. and Karnovsky L. M. (1980) Active oxygen species and the functions of phagocytic leukocytes. Ann. Rev. Biochem.49: 695–726.
Cerutti P. A. (1985): Prooxidant states and tumor promotion. Science227: 375–381
Halliwell B. and Gutteridge J. M. C. (1985) Free radicals in biology and medicine, Clarendon Press, Oxford
Balazs R. and Brooksbank B. W. L. (1985) Neurochemical approaches to the pathogenesis of Down's syndrome. J. Ment. Defic. Res.29: 1–14
Groner Y., Lieman-Hurwitz J., Dafni N., Sherman L., Levanon D., Bernstein Y., Danciger E. and Elroy-Stein O. (1986) Molecular structure and expression of the gene locus on chromosome 21 encoding the Cu/Zn-superoxide dismutase and its relevance to Down's syndrome. Ann. N. Y. Acad. Sci.450: 133–156
Minami M. and Yoshikawa H. (1979) A simplified assay method of superoxide dismutase activity for clinical use. Clin. Chim. Acta92: 337–342
McCord J. M. and Fridovich I. (1969) Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem.244: 6049–6055
Aula P., Leisti J. and Von Koskull H. (1973) Partial trisomy 21. Clin. Genet.4: 241–251
Sinet P. M., Couturier J., Dutrillaux B., Poissonier M., Raoul O., Rethore M. O., Allard D., Lejeune J. and Jerome H. (1976) Trisomie 21 et superoxide dismutase 1 (IPO-A): tentative de localisation sur la sousbande 21q221. Exp. Cell. Res.97: 47–55
Hagemeijer A. and Smit E. M. E. (1977) Partial trisomy 21: further evidence that trisomy of band 21q22 is essential for Down's phenotype. Hum. Genet.38: 15–23
Kedziora J., Bartorz G., Keyko W. and Rosynkawa D. (1979) Dismutase activity in traslocation trisomy. Lancet1: 105
Mattei J. F., Mattei M. G., Baeteman M. A. and Giraud F. (1981) Trisomy 21 for the region 21q223: identification by high resolution R banding patterns. Hum. Genet.56: 409–411
Miyazaki K., Yamanaka T. and Ogasawara N. (1987) A boy with Down's syndrome having recombinant chromosome 21 but no SOD-1 excess. Clin. Genet.32: 383–387
Jeziorowska A., Jakubowski L., Lach J. and Kaluzewski B. (1988) Regular trisomy 21 not accompanied by increased copper-zinc superoxide dismutase (SOD-1) activity. Clin. Genet.33: 11–19
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De La Torre, R., Casado, A., López-Fernández, E. et al. Overexpression of copper-zinc superoxide dismutase in trisomy 21. Experientia 52, 871–873 (1996). https://doi.org/10.1007/BF01938872
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01938872